tildrakizumab   

GtoPdb Ligand ID: 8093

Synonyms: Ilumetri® | Ilumya® | MK-3222 | MK3222 | SCH-900222 | SCH900222 | SUNPG1623 | tildrakizumab-asmn
tildrakizumab is an approved drug (EMA & FDA (2018))
Compound class: Antibody
Comment: Tildrakizumab is a monoclonal antibody directed against the p19 subunit of IL-23 (IL-23A). It exhibits efficacy in treating psoriasis [1,4]. This biologic agent may be beneficial for patients who do not tolerate current antitumour necrosis factor (TNF) therapies.
Immunopharmacology Comments
Tildrakizumab inhibits IL-23 receptor signalling by sequestering free ligand. This action down modulates the release of pro-inflammatory cytokines and chemokines, and reduces disease pathology.
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
Approved drug for moderate to severe plaque psoriasis. 3